32 46

Cited 0 times in

Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes

 Seung Ho Baek  ;  Soon June Bae  ;  Chang Ik Yoon  ;  So Eun Park  ;  Chi Hwan Cha  ;  Sung Gwe Ahn  ;  Young Seok Kim  ;  Tai Suk Roh  ;  Joon Jeong 
 JOURNAL OF BREAST CANCER, Vol.22(1) : 109-119, 2019 
Journal Title
Issue Date
Breast implants ; Breast neoplasm ; Chemotherapy, adjuvant ; Radiotherapy, adjuvant ; Recurrence
Purpose: The use of immediate breast reconstruction (IBR) has been debated because it may be a causative factor in adjuvant treatment delay and may subsequently increase the probability of recurrence. We investigated whether IBR was related to adjuvant treatment delay and survival outcomes. Methods: We retrospectively analyzed the duration from operation to adjuvant treatment administration and survival outcomes according to IBR status among patients with breast cancer who underwent mastectomy followed by adjuvant chemotherapy from January 2005 to December 2014. Propensity score matching was performed to balance the clinicopathologic baseline characteristics between patients who did and did not undergo IBR. Results: Of 646 patients, 107 (16.6%) underwent IBR, and the median follow-up was 72 months. The median duration from surgery to adjuvant chemotherapy was significantly longer in patients who underwent IBR than in those who did not (14 vs. 12 days, respectively, p = 0.008). Based on propensity score matching, patients who underwent IBR received adjuvant therapy 3 days later than those who did not (14 vs. 11 days, respectively, p = 0.044). The duration from surgery to post-mastectomy radiation therapy (PMRT) did not significantly differ between the 2 groups. Local recurrence-free survival, regional recurrence-free survival, systemic recurrence-free survival, and overall survival were also not significantly different between the 2 groups (p = 0.427, p = 0.445, p = 0.269, and p = 0.250, respectively). In the case-matched cohort, survival outcomes did not change. Conclusion: IBR was associated with a modest increase in the duration from surgery to chemotherapy that was statistically but not clinically significant. Moreover, IBR had no influence on PMRT delay or survival outcomes, suggesting that it is an acceptable option for patients with non-metastatic breast cancer undergoing mastectomy.
Files in This Item:
T201901586.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Plastic and Reconstructive Surgery (성형외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Young Seok(김영석) ORCID logo https://orcid.org/0000-0002-0981-2107
Roh, Tai Suk(노태석) ORCID logo https://orcid.org/0000-0001-8681-159X
Park, So Eun(박소은)
Bae, Soong June(배숭준) ORCID logo https://orcid.org/0000-0002-0012-9694
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Yoon, Changik(윤창익)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Cha, Chi Hwan(차치환)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.